Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nomifensine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 12/20 | 0.81 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 0.81 |
| ▸ | SLC6A3 known ✓ | Q01959 | 12/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nomifensine SCHEMBL10538258 | 1.00 | LMNA (1.00) | LMNAMAPK1MEN1GLAPOLB | |
| Nomifensine SCHEMBL29355061 | 0.90 | SLC6A2 (1.00) | LMNAMAPK1MEN1GLAPOLB | |
| Nomifensine SCHEMBL125020 | 0.90 | SLC6A2 (1.00) | LMNAMAPK1MEN1GLAPOLB | |
| Nomifensine SCHEMBL49380 | 0.90 | SLC6A2 (1.00) | LMNAMAPK1MEN1GLAPOLB | |
| Nomifensine SCHEMBL11082568 | 0.88 | SLC6A2 (0.97) | LMNAMAPK1MEN1GLAPOLB | |
| Maleic Acid SCHEMBL11657098 | 0.86 | SLC6A4 (0.81) | LMNAMAPK1MEN1GLAPOLB | |
| Nomifensine SCHEMBL12496276 | 0.85 | MAPK1 (0.72) | LMNAMAPK1MEN1GLAPOLB | |
| SCHEMBL4035368 | 0.81 | SLC6A2 (0.77) | LMNAMAPK1MEN1GLAPOLB | |
| Bromide SCHEMBL11267146 | 0.80 | SLC6A2 (0.75) | LMNAMAPK1MEN1GLAPOLB | |
| SCHEMBL11013456 | 0.79 | SLC6A2 (0.79) | LMNAMAPK1MEN1GLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 642 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114466859-A | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof | 田中纯美 | 2022-05-10 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-4806548-A | 4-PHENYL-TETRAHYDROISOQUINOLINE ANTIDEPRESSANT, CIMETIDINE, AND RANITIDINE; HISTAMINE H-2-ANTAGONISTS | T P O PHARMACHIM (BG) | 1989-02-21 | — | — | US | claimed |
| US-4207309-A | FOR DIFFERENTIATING BETWEEN HYPERPROLACTINEMIA DUE TO PITUITARY TUMORS AND FUNCTIONAL CASES | MULLER EUGENIO E | 1980-06-10 | — | — | US | claimed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-0066885-B1 | PROCESS FOR THE PREPARATION OF N-(2-AMINOBENZYL)-1-PHENYL-2-METHYLAMINO-ETHANOL | DSO "PHARMACHIM" (BG) | 1985-10-09 | — | — | EP | disclosed |
| US-4537895-A | 4-PHENYL, 8-CARBONYLAMINO DERIVATIVES FOR CENTRAL NERVOUS SYSTEM DISORDERS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1985-08-27 | — | — | US | disclosed |
| US-4340600-A | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1982-07-20 | — | — | US | disclosed |
| US-4207309-A | FOR DIFFERENTIATING BETWEEN HYPERPROLACTINEMIA DUE TO PITUITARY TUMORS AND FUNCTIONAL CASES | MULLER EUGENIO E | 1980-06-10 | — | — | US | disclosed |
| US-4207309-A | FOR DIFFERENTIATING BETWEEN HYPERPROLACTINEMIA DUE TO PITUITARY TUMORS AND FUNCTIONAL CASES | MULLER EUGENIO E | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | SLC6A2 82/4885SLC6A4 64/4885SLC6A3 10/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SLC6A2 1338/4885SLC6A4 1763/4885SLC6A3 1329/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SLC6A2 286/4885SLC6A4 120/4885SLC6A3 291/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | SLC6A2 369/4885SLC6A4 448/4885SLC6A3 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.